Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN632 monotherapy in CD123-positive AML and other hematologic malignancies
2024-514195-40-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of pivekimab sunirine in acute myeloid leukemia (AML), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute lymphoblastic leukemia (ALL) and 4 more (7 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum tolerated dose and recommended Phase 2 dose and Complete remission plus clinical complete remission. Started Feb 2019; status: completed.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2024-514195-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514195-40-00.